Skip to content
value.today

Celularity Inc.: peers

Change the peers

Celularity Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

CytRx Corporation: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Celularity Inc., ABVC BioPharma, Inc., BioStem Technologies, Inc., CervoMed Inc., CEL-SCI Corporation, IGC Pharma, Inc., CytRx Corporation, NextCure, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureCelularity Inc.base
CELU · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
ABVC BioPharma, Inc.
ABVC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
BioStem Technologies, Inc.
BSEM · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
CervoMed Inc.
CRVO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
CEL-SCI Corporation
CVM · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
IGC Pharma, Inc.
IGC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
CytRx Corporation
CYTR · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
NextCure, Inc.
NXTC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$28 MOct 30, 2026 · Market data5th of 8$28 MOct 30, 2026 · Market data4th of 8$29 MOct 29, 2026 · Market data3rd of 8$26 MOct 30, 2026 · Market data6th of 8$26 MOct 30, 2026 · Market data7th of 8$29 MOct 26, 2026 · Market data2nd of 8$26 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one8th of 8$30 MOct 30, 2026 · Market data1st of 8$28 M8 ranked
Revenue (Better neither way: ranked highest first)$27 MFY2025 · SEC2nd of 4$0 MFY2025 · SEC4th of 4$47 MFY2025 · SEC1st of 4$4 MFY2025 · SEC3rd of 4————————$15 M4 ranked
Net income (Higher is better)$-92 MFY2025 · SEC7th of 7$-8 MFY2025 · SEC3rd of 7$-7 MFY2025 · SEC2nd of 7$-27 MFY2025 · SEC5th of 7$-25 MFY2025 · SEC4th of 7——$-2 MFY2024 · SEC1st of 7$-56 MFY2025 · SEC6th of 7$-25 M7 ranked
Employees (Better neither way: ranked highest first)288As on July 2022 · Profile1st of 2————15December 31, 2025 · Profile2nd of 2————————1522 ranked
Growth
Revenue growth (Higher is better)-51.0%FY2025 · SEC2nd of 33rd1st————-31.8%FY2025 · SEC1st of 37th4th-58.8%FY2025 · SEC3rd of 32nd1st————————————————-51.0%3 ranked
Revenue growth, 3 years a year (Higher is better)+13.9%FY2025 · SEConly one with it62nd78th————————————————————————————+13.9%—
Margins and returns
Gross margin (Higher is better)24.4%FY2025 · SEC2nd of 212th26th————93.6%FY2025 · SEC1st of 295th98th————————————————————59.0%2 ranked
Operating margin (Higher is better)-230.9%FY2025 · SEC2nd of 314th5th————-1.4%FY2025 · SEC1st of 356th38th-705.5%FY2025 · SEC3rd of 33rd1st————————————————-230.9%3 ranked
Net margin (Higher is better)-345.5%FY2025 · SEC2nd of 39th3rd————-13.9%FY2025 · SEC1st of 346th24th-672.6%FY2025 · SEC3rd of 33rd1st————————————————-345.5%3 ranked
Free cash flow margin (Higher is better)————————13.9%FY2025 · SEConly one with it78th78th————————————————————13.9%—
Return on equity (Higher is better)————-128.2%FY2025 · SEC4th of 519th8th-16.6%FY2025 · SEC1st of 562nd29th-93.9%FY2025 · SEC2nd of 526th11th-176.3%FY2025 · SEC5th of 513th5th————————-111.2%FY2025 · SEC3rd of 522nd10th-111.2%5 ranked
Valuation
Price to sales (Better neither way: ranked highest first)1.5×price Oct 30, 2026 · Market data4th of 524th39th93.5×price Oct 30, 2026 · Market data1st of 594th98th0.7×price Oct 29, 2026 · Market data5th of 512th21st6.6×price Oct 30, 2026 · Market data3rd of 563rd83rd————24.9×price Oct 26, 2026 · Market data2nd of 585th95th————————6.6×5 ranked
Price to book (Better neither way: ranked highest first)————2.5×price Oct 30, 2026 · Market data2nd of 643rd56th0.7×price Oct 29, 2026 · Market data6th of 613th13th1.4×price Oct 30, 2026 · Market data4th of 629th35th1.6×price Oct 30, 2026 · Market data3rd of 633rd40th3.9×price Oct 26, 2026 · Market data1st of 659th70th————0.9×price Oct 30, 2026 · Market data5th of 616th16th1.6×6 ranked
Free cash flow yield (Higher is better)-23.8%price Oct 30, 2026 · Market data4th of 730th13th-15.0%price Oct 30, 2026 · Market data2nd of 737th17th22.8%price Oct 29, 2026 · Market data1st of 798th96th-48.3%price Oct 30, 2026 · Market data5th of 719th8th-65.0%price Oct 30, 2026 · Market data6th of 714th5th-16.8%price Oct 26, 2026 · Market data3rd of 736th16th————-138.0%price Oct 30, 2026 · Market data7th of 74th1st-23.8%7 ranked
Financial strength
Debt to equity (Lower is better)————————0.0×FY2025 · SEC1st of 25th3rd————————0.0×FY2025 · SEC2nd of 212th8th————————0.0×2 ranked
Interest cover (Higher is better)————-715.0×FY2025 · SEC2nd of 23rd1st————————-38.2×FY2025 · SEC1st of 224th11th————————————-376.6×2 ranked
Piotroski F-score (Higher is better)————5 of 9FY2025 · SEConly one with it——————————5.0 of 9—
Scorecard
Scorecard (Higher is better)4 of 19FY2025 · Scorecard6th of 82 of 16FY2025 · Scorecard8th of 89 of 15FY2025 · Scorecard1st of 83 of 14FY2025 · Scorecard5th of 83 of 13FY2025 · Scorecard4th of 82 of 8FY2025 · Scorecard3rd of 82 of 7FY2024 · Scorecard2nd of 82 of 14FY2025 · Scorecard7th of 822% passed8 ranked
Valuation checks (Higher is better)1 of 5FY2025 · Scorecard5th of 71 of 5FY2025 · Scorecard5th of 73 of 5FY2025 · Scorecard1st of 72 of 5FY2025 · Scorecard2nd of 71 of 4FY2025 · Scorecard3rd of 70 of 5FY2025 · Scorecard7th of 7——1 of 4FY2025 · Scorecard3rd of 725% passed7 ranked
Growth checks (Higher is better)3 of 6FY2025 · Scorecard1st of 71 of 3FY2025 · Scorecard4th of 70 of 2FY2025 · Scorecard5th of 70 of 2FY2025 · Scorecard5th of 71 of 2FY2025 · Scorecard1st of 7——1 of 2FY2024 · Scorecard1st of 70 of 2FY2025 · Scorecard5th of 733% passed7 ranked
Profitability checks (Higher is better)0 of 4FY2025 · Scorecard2nd of 70 of 3FY2025 · Scorecard2nd of 71 of 3FY2025 · Scorecard1st of 70 of 4FY2025 · Scorecard2nd of 70 of 3FY2025 · Scorecard2nd of 7——0 of 2FY2024 · Scorecard2nd of 70 of 3FY2025 · Scorecard2nd of 70% passed7 ranked
Financial health checks (Higher is better)0 of 3FY2025 · Scorecard6th of 80 of 4FY2025 · Scorecard6th of 84 of 4FY2025 · Scorecard1st of 81 of 3FY2025 · Scorecard4th of 81 of 3FY2025 · Scorecard4th of 82 of 3FY2025 · Scorecard2nd of 80 of 2FY2024 · Scorecard6th of 81 of 2FY2025 · Scorecard3rd of 833% passed8 ranked
Shareholder returns checks (Higher is better)0 of 1FY2025 · Scorecard3rd of 60 of 1FY2025 · Scorecard3rd of 61 of 1FY2025 · Scorecard1st of 6——0 of 1FY2025 · Scorecard3rd of 6——1 of 1FY2024 · Scorecard1st of 60 of 3FY2025 · Scorecard3rd of 60% passed6 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)6.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 74.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 79.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 78.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 711.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 75.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7——67.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 78.8%7 ranked
Institutions holding (Better neither way: ranked highest first)332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7152026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7262026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7442026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7292026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7——332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7337 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)-0.7 pp2026-Q2 against 2026-Q1 · 13F4th of 6+0.9 pp2026-Q2 against 2026-Q1 · 13F2nd of 6——-7.5 pp2026-Q2 against 2026-Q1 · 13F5th of 6+2.6 pp2026-Q2 against 2026-Q1 · 13F1st of 6+0.7 pp2026-Q2 against 2026-Q1 · 13F3rd of 6——-22.1 pp2026-Q2 against 2026-Q1 · 13F6th of 6-0.0 pp6 ranked
Dividends
Dividend per share (Better neither way: ranked highest first)——————————————$0.00FY2025 · SEConly one with it$0.00—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Celularity Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; ABVC BioPharma, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; BioStem Technologies, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CervoMed Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CEL-SCI Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; IGC Pharma, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CytRx Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; NextCure, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Celularity Inc.-230.9%FY2025
14th percentile in Healthcaremedian -7.7%, 674 companies
5th percentile in USAmedian 3.5%, 2,594 companies
ABVC BioPharma, Inc.———
BioStem Technologies, Inc.-1.4%FY2025
56th percentile in Healthcaremedian -7.7%, 674 companies
38th percentile in USAmedian 3.5%, 2,594 companies
CervoMed Inc.-705.5%FY2025
3rd percentile in Healthcaremedian -7.7%, 674 companies
1st percentile in USAmedian 3.5%, 2,594 companies
CEL-SCI Corporation———
IGC Pharma, Inc.———
CytRx Corporation———
NextCure, Inc.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$17 M$35 M$52 M$70 M20102012201420162018202020222024Celularity Inc. $27 MABVC BioPharma, Inc. $0 MBioStem Technologies, Inc. $47 MCervoMed Inc. $4 MCEL-SCI Corporation $0 MIGC Pharma, Inc. $1 MCytRx Corporation $0 MNextCure, Inc. $22 M

Rank in the group

1st2nd3rd4th5th2011201220132014201720182019202020212022202320242025Celularity Inc.: 2nd of 4 in 2020Celularity Inc.: 1st of 3 in 2021Celularity Inc.: 1st of 3 in 2022Celularity Inc.: 1st of 4 in 2023Celularity Inc.: 2nd of 5 in 2024Celularity Inc.: 2nd of 4 in 2025Celularity Inc.ABVC BioPharma, Inc.: 4th of 4 in 2012ABVC BioPharma, Inc.: 3rd of 3 in 2013ABVC BioPharma, Inc.: 3rd of 3 in 2019ABVC BioPharma, Inc.: 4th of 4 in 2020ABVC BioPharma, Inc.: 3rd of 3 in 2021ABVC BioPharma, Inc.: 2nd of 3 in 2022ABVC BioPharma, Inc.: 4th of 4 in 2023ABVC BioPharma, Inc.: 5th of 5 in 2024ABVC BioPharma, Inc.: 4th of 4 in 2025ABVC BioPharma, Inc.BioStem Technologies, Inc.: 1st of 5 in 2024BioStem Technologies, Inc.: 1st of 4 in 2025BioStem Technologies, Inc.CervoMed Inc.: 3rd of 4 in 2011CervoMed Inc.: 2nd of 4 in 2012CervoMed Inc.: 2nd of 3 in 2013CervoMed Inc.: 2nd of 4 in 2023CervoMed Inc.: 3rd of 5 in 2024CervoMed Inc.: 3rd of 4 in 2025CervoMed Inc.CEL-SCI Corporation: 2nd of 4 in 2011CEL-SCI Corporation: 3rd of 4 in 2012CEL-SCI Corporation: 1st of 3 in 2013CEL-SCI Corporation: 2nd of 2 in 2014CEL-SCI CorporationIGC Pharma, Inc.: 1st of 4 in 2011IGC Pharma, Inc.: 1st of 4 in 2012IGC Pharma, Inc.: 1st of 2 in 2014IGC Pharma, Inc.: 1st of 2 in 2017IGC Pharma, Inc.: 1st of 2 in 2018IGC Pharma, Inc.: 2nd of 3 in 2019IGC Pharma, Inc.: 3rd of 4 in 2020IGC Pharma, Inc.: 2nd of 3 in 2021IGC Pharma, Inc.: 3rd of 3 in 2022IGC Pharma, Inc.: 3rd of 4 in 2023IGC Pharma, Inc.: 4th of 5 in 2024IGC Pharma, Inc.CytRx Corporation: 4th of 4 in 2011CytRx Corporation: 2nd of 2 in 2017CytRx Corporation: 2nd of 2 in 2018CytRx CorporationNextCure, Inc.: 1st of 3 in 2019NextCure, Inc.: 1st of 4 in 2020NextCure, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearCelularity Inc.ABVC BioPharma, Inc.BioStem Technologies, Inc.CervoMed Inc.CEL-SCI CorporationIGC Pharma, Inc.CytRx CorporationNextCure, Inc.
2025$27 MSEC2nd$0 MSEC4th$47 MSEC1st$4 MSEC3rd————
2024$54 MSEC2nd$1 MSEC5th$70 MSEC1st$10 MSEC3rd—$1 MSEC4th——
2023$23 MSEC1st$0 MSEC4th—$7 MSEC2nd—$1 MSEC3rd——
2022$18 MSEC1st$1 MSEC2nd———$1 MSEC3rd——
2021$21 MSEC1st$0 MSEC3rd———$0 MSEC2nd——
2020$14 MSEC2nd$0 MSEC4th———$1 MSEC3rd—$22 MSEC1st
2019—$1 MSEC3rd———$4 MSEC2nd—$6 MSEC1st
2018—————$5 MSEC1st$0 MSEC2nd—
2017—————$2 MSEC1st$0 MSEC2nd—
2016—————$1 MSEC——
2015—————$6 MSEC——
2014————$0 MSEC2nd$8 MSEC1st——

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Celularity Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • ABVC BioPharma, Inc.ABVC · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $28 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $28 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • BioStem Technologies, Inc.BSEM · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $29 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $29 M (Oct 29, 2026) · revenue $47 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • CervoMed Inc.CRVO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $26 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $26 M (Oct 30, 2026) · revenue $4 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • CEL-SCI CorporationCVM · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $26 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $26 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • IGC Pharma, Inc.IGC · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $29 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $29 M (Oct 26, 2026) · revenue $1 M (year to March 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • CytRx CorporationCYTR · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $26 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $26 M (last known, Jan 7, 2022)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • NextCure, Inc.NXTC · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $30 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $30 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Atossa GeneticsATOS · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $26 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $26 M (Oct 14, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Metagenomi Therapeutics, Inc.MGX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $30 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $30 M (Oct 28, 2026) · revenue $25 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Protokinetix IncorporatedPKTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $25 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $25 M (last known, Jan 7, 2022)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Agentix Corp.AGTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $31 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $31 M (last known, Jan 7, 2022)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • AEON Biopharma, Inc.AEON · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $24 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $24 M (Oct 30, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.